WO1992021680A1 - Composes derives des aza-6-indoles, ligands du recepteur des benzodiazepines et medicaments le contenant - Google Patents
Composes derives des aza-6-indoles, ligands du recepteur des benzodiazepines et medicaments le contenant Download PDFInfo
- Publication number
- WO1992021680A1 WO1992021680A1 PCT/FR1992/000480 FR9200480W WO9221680A1 WO 1992021680 A1 WO1992021680 A1 WO 1992021680A1 FR 9200480 W FR9200480 W FR 9200480W WO 9221680 A1 WO9221680 A1 WO 9221680A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- formula
- compound
- hydrogen atom
- group
- Prior art date
Links
- 0 CC1=C(C=C(*)N)C(*=C)=C(*O)I=C1 Chemical compound CC1=C(C=C(*)N)C(*=C)=C(*O)I=C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to new derivatives of 6-azamdole iigands of the benzodiazepine receptor, to pharmaceutical compositions containing these compounds, to processes for obtaining said compounds and also to compounds useful in particular as intermediates in preparation processes.
- Benzodiazepines-1, 4 are a class of widely prescribed drugs because of their anxiolytic, anticonvulsant, sedative-hypnotic and muscle relaxant activities.
- the mechanism of action of benzodiazepines remained unknown for a long time until the identification of specific binding sites (or "receptors") for these molecules on the neuronal membranes of the central nervous system.
- receptors specific binding sites for these molecules on the neuronal membranes of the central nervous system.
- the physiological importance of these receptors has been demonstrated by the existence of a good correlation between, on the one hand, the value of the affinity of the different benzodiazepines for the receptor (measured by displacement of a radioactive benzodiazepine) and, on the other hand, their therapeutic efficacy.
- ZK 93423 and ZK 91296 also have properties similar to those of diazepam in vivo (anxiolytic, anticonvulsant, etc.).
- ⁇ -CCE ⁇ -carboIine-3-carboxylic acid
- reverse agonist is now used to refer to those benzodiazepine receptor ligands which have activities wholly or partially opposite to those of the benzodiazepines.
- Benzodiazepine receptor inverse agonists have a positive effect on learning and memory (Venault et al., Nature, 321, 864-866, 1986). Although ⁇ -CCM could not be tested in humans for its prominent effects due to its highly convulsive activity, other analogs such as ZK 93426 or Flumazenil, benzodiazepine receptor antagonists, have been tested in humans where their promnesic properties have been demonstrated (Duka et al. Psychopharmacology, 93, 42-427, 1987 and Lai et al., Pharmacol. Biochem. Behav., 35, 747-750, 1990).
- partial antagonists or agonists of the benzodiazepine receptor are useful in the treatment of certain cognitive problems such as Alzheimer's disease.
- aza-6-indoie derivatives are known, some of which have been tested for their property on the central nervous system.
- R " H, CO 2 H, CO 2 C 2 H 5 , CONH 2 , CN, C 6 H 5 , CHO, CH 2 OH None of these molecules are known to interact with the benzodiazepine receptor.
- patent DE-A-3,525,928 describes the synthesis of derivatives of 5, 6, 7, 8-tetrahydro- ⁇ - carboline.
- one of the aims of the present invention is to provide new compounds which have an affinity for the benzodiazepine receptor while having an at least partial reverse agonist effect.
- Another object of the present invention is to provide new therapeutic compositions useful in particular in the treatment of nervous disorders.
- Another object of the present invention is to propose new therapeutic compositions having a positive effect on learning and memorization and which can be used for the treatment of cognitive problems such as, for example, in Alzheimer's disease.
- the invention relates firstly to the 6-azaindole of formula:
- R 1 represents the hydrogen atom or a group R 5 -O-CH 2 - in which R 5 corresponds to an alkyl radical optionally substituted by one or more alkoxy, alkylthio, alkylcarbonyl, amino, nitro, cyano or a group of formula Ar-Z,
- R 2 is an alkoxy, cycloalkoxy, aryloxy, araicoxy, substituted amino-N'-alkyl, substituted amino-N-cycloalkyie, substituted amino-N-phenyl radical, the aromatic parts possibly being substituted,
- R 3 , R 4 independently represent the hydrogen atom or an alkyl radical
- R 1 , R 3 , R 4 are the hydrogen atom
- R 2 is the am ⁇ no-N- (2-carboxyphenyl) radical
- the alkyl and alkoxy radicals preferably have from 1 to 6 carbon atoms and can be linear or branched (preferably linear).
- the aryl and aryloxy radicals preferably have 6 to 10 carbon atoms and the aralkyl and araicoxy radicals from 7 to 11 carbon atoms.
- heteroaryy radicals mention may be made of 1- or 2- or 3-pyridyl, 1- or 2- or 3-pyrrolyl, 2- or 3-thiophenyl, 2- or 3-furanyie, 1- or 2- or 3- or 4- ⁇ midazolyie, the various pyrimydinyl radicals.
- halogen atoms such as halogen atoms, nitro, cyano, alkoxy radicals, optionally halogenated, C 1 -C 3 linear alkyl for C 3 , optionally halogen, CF , in particular, SO 3 H.
- certain compounds have one or more centers of asymmetry. They can therefore exist in one or more optically active forms.
- the invention comprises said optically active forms of these compounds.
- the group R 1 corresponds to the group of formula
- - X is a donor electron radical, of small bulk
- - n is a positive or zero integer, less than 6, the groups X being able to be identical or different when n is greater than 1,
- the group R 1 corresponds to the group of formula III:
- R 1 is a methyl group substituted by an alkoxy radical and preferably, COR 2 is an ester function.
- R 1 is a hydrogen atom and preferably COR 2 is an amide function, advantageously R 2 being an N-aryl amide, in particular N-phenylamide optionally substituted by one or more radicals chosen from carboxy radicals , sulfonate or acid phosphonate. It has in fact been unexpectedly found that certain amides according to the invention have affinities with respect to the rat cortex, greater than those of esters.
- amide group molecules are provided for the first time having good properties relating to the desired objective. These molecules also have several advantages:
- the invention also relates to the processes for preparing the compounds according to the invention.
- This process consists in reacting a compound of formula:
- R 6 , R 7 independently are the hydrogen atom or a C 1 -C 4 alkyl radical
- R 8 is (C 1 -C 4 ) alkyl, (C 3 -C 6 ) cycloalkyl, (C 6 -C 10 ) aryl, (C 7 -C 1 1 ) aralkyl, the aromatic rings being optionally substituted as for R 2 ,
- the compound of formula IV is prepared by reaction of a compound of formula:
- obtaining the amide function is ensured seion the indications of the publication of Dellouve-Courillon above.
- the compound of formula VII is prepared by esterification of the corresponding acid VI which is itself prepared by oxidation of the aldehyde VIII. This is obtained in a known manner, for example according to the reaction scheme described in the publication by Dellouve-Courillon et al. cited above.
- the invention also relates to the drugs consisting of one of the compounds according to the invention, and the compound of formula I in which R 1 , R 3 , R 4 are the hydrogen atom and R 2 the am ⁇ no-N- radical ( 2-carboxyphenyl) as just described above and the compositions pharmaceuticals containing at least one of these drugs and an acceptable carrier.
- These drugs and compositions are useful for the medical or veterinary treatment of certain disorders related to the functioning of the nervous system.
- These drugs and compositions can thus advantageously be intended to participate in an effective therapy against degenerative diseases of the nervous system, in particular dementias of the Alzheimer type.
- compositions are in particular formulated to be ingested orally or to be injected.
- other presentations can also be envisaged in the context of the present invention.
- the dosage will depend partly on the disease to be treated as well as its severity and also on the type of individual (weight, age).
- a dosage ranging from 0.1 mg / kg to 20 mg / kg may advantageously be considered.
- reaction medium is then cooled and concentrated in vacuo. It is then basified with a saturated sodium bicarbonate solution and the extraction is carried out with dichloromethane. The organic phases are combined, washed with water and then a sodium chloride solution is dried over magnesium sulfate. The solvent is evaporated under reduced pressure, leaving a residue which is crystallized from a mixture of dichloromethane and acetonitrile to yield 171.2 mg (43%) of azagramine.
- Examples 1 to 14 were tested on a rat cortex membrane in order to determine their affinity for the benzodiazepine receptor.
- This study consists of an electrophysiological test on Xenopus oocyte.
- Chicken optic lobe cells incidentally exhibit a good response to GABA.
- the total RNAs are extracted therefrom and passed through an oligodT affinity column, thus making it possible to separate the crude messenger RNAs therefrom, since these have a polyA terminal end which will associate by complementarity with the oligodT residues of the column.
- These messenger RNAs will then be injected into a Xenopus oocyte, which is only one single cell.
- oocytes will then be incubated, and in two days, the messenger RNA will be expressed and will thus, thanks to the cellular machinery of the oocyte, produce GABA receptor complexes - benzodiazepine receptor - chloride channel. These large protein entities will then migrate into the cell and reach the membrane, thus allowing this receptor and the transmembrane ion channel associated with it to take its place.
- the oocyte is then placed in a 10 - 5 M GABA bath in RINGER solute and two microelectrodes A and B are introduced there, a third microelectrode being placed outside the cell to serve as a reference.
- Microelectrode A will be used to measure the potential difference (PDD) between the inside and the outside of the oocyte.
- a 60 mV PDD is imposed on the oocyte, and microelectrode B will be used to maintain this desired PDD.
- GABA present in the medium will exert an allosteric effect at the level of the receptor with as a corollary the opening of the ion channel. There will therefore be entry of chloride into the oocyte, and the PDD will increase a lot.
- an inverse agonist like ⁇ -CCM will cause a reduction in the binding of GABA to the receptor with as a consequence a reduction in the opening time of the chloride channel and a lower DDP.
- An antagonist will occupy the benzodiazepine receptor binding site but will have no effect on the binding of GABA. The opening of the chloride channel will therefore not be disturbed, and the PDD will not vary.
- Compound 1 was perfused into the medium bathing the oocyte at a concentration of 10 -6 M, causing, compared to the sharp increase in diazepam and the significant decrease in ⁇ -CCM, a slight decrease in DDP. Molecule 1 is therefore a partial inverse agonist, while ZK 91296 is a partial agonist.
- Compound 1 was first tested for its convulsive properties. The test was carried out on 14 two month old mice (5 males and 9 females) belonging to the ABP / Le strain. This particular strain is very sensitive to convulsions induced by ⁇ -carbines. Compound 1 was administered intraperitoneally at a dose of 20 mg / kg and the observation took place after 30 minutes. None of the mice exhibited any convulsions. The compound is therefore not convulsive.
- Compound 1 was then tested on learning. This test, passive avoidance with learning in a single trial, was performed on 30 two-month-old Swiss female mice. Compound 1 was administered to 15 mice at a dose of 20 mg / kg, the other 15 receiving an injection of physiological saline.
- the equipment consists of a white box connected to a black box by a door.
- the white box is lit by a 100 W lamp placed at 25 cm, and the black box, in which the mouse will go spontaneously because it feels safe in the dark, has an electrified metal floor.
- the boxes are coated with mouse odor by an animal placed in front of each of the two sets of 15 mice.
- the test takes place in two sessions: the first is learning, and the second, which takes place 24 hours later, is the avoidance test itself.
- the marked mice receive an intra-pe ⁇ tonéale injection of physiological saline or of compound 1.
- the injection is made with the test in order to check if the tested molecule acts on the memory at the level of the phenomenon- d 'acquisition. If the information retention phase had been studied, the injection would have taken place after the learning test.
- the mice are then placed one by one in the illuminated white box, and the arrival latency in the black box is noted. This time is on average 24 seconds, and the criterion used is that the four legs of the mouse are in the black box. At this precise moment, an electric shock of 75 ⁇ A of direct current is triggered for two seconds.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/142,489 US5484793A (en) | 1991-05-29 | 1992-05-29 | Compounds derived from 6-azaindoles as ligands of the benzodiazepine receptor and medicaments containing them |
JP4511067A JPH06508120A (ja) | 1991-05-29 | 1992-05-29 | ベンゾジアゼピンレセプターのリガンドとして6−アザインドール類から誘導された化合物とそれらを含有した薬剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9106453A FR2677024B1 (fr) | 1991-05-29 | 1991-05-29 | Composes derives des aza-6-indoles, ligands du recepteur des benzodiazepines et medicaments les contenant. |
FR91/06453 | 1991-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992021680A1 true WO1992021680A1 (fr) | 1992-12-10 |
Family
ID=9413230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1992/000480 WO1992021680A1 (fr) | 1991-05-29 | 1992-05-29 | Composes derives des aza-6-indoles, ligands du recepteur des benzodiazepines et medicaments le contenant |
Country Status (6)
Country | Link |
---|---|
US (1) | US5484793A (fr) |
EP (1) | EP0586526A1 (fr) |
JP (1) | JPH06508120A (fr) |
CA (1) | CA2110299A1 (fr) |
FR (1) | FR2677024B1 (fr) |
WO (1) | WO1992021680A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024435A1 (fr) * | 1996-12-06 | 1998-06-11 | Merck Sharp & Dohme Limited | Utilisation de 2-(4-methoxyphenyle)-pyrazolo(4,3-c)quinoleine-3-one pour la preparation d'un medicament nootrope |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0217737A2 (fr) * | 1985-10-04 | 1987-04-08 | Schering Aktiengesellschaft | Tétrahydro-bêta-carbolines, leur procédé de préparation et leur application comme médicaments |
-
1991
- 1991-05-29 FR FR9106453A patent/FR2677024B1/fr not_active Expired - Lifetime
-
1992
- 1992-05-29 WO PCT/FR1992/000480 patent/WO1992021680A1/fr not_active Application Discontinuation
- 1992-05-29 CA CA002110299A patent/CA2110299A1/fr not_active Abandoned
- 1992-05-29 EP EP92912278A patent/EP0586526A1/fr not_active Withdrawn
- 1992-05-29 US US08/142,489 patent/US5484793A/en not_active Expired - Fee Related
- 1992-05-29 JP JP4511067A patent/JPH06508120A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0217737A2 (fr) * | 1985-10-04 | 1987-04-08 | Schering Aktiengesellschaft | Tétrahydro-bêta-carbolines, leur procédé de préparation et leur application comme médicaments |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024435A1 (fr) * | 1996-12-06 | 1998-06-11 | Merck Sharp & Dohme Limited | Utilisation de 2-(4-methoxyphenyle)-pyrazolo(4,3-c)quinoleine-3-one pour la preparation d'un medicament nootrope |
US6087372A (en) * | 1996-12-06 | 2000-07-11 | Merck Sharp & Dohme Ltd. | Method of enhancing cognition with 2-(4-methoxyphenyl)-pyrazolo[4,3-c]quinolin-3-one |
Also Published As
Publication number | Publication date |
---|---|
CA2110299A1 (fr) | 1992-12-10 |
EP0586526A1 (fr) | 1994-03-16 |
JPH06508120A (ja) | 1994-09-14 |
FR2677024A1 (fr) | 1992-12-04 |
US5484793A (en) | 1996-01-16 |
FR2677024B1 (fr) | 1995-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0172096B1 (fr) | Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique | |
CA2150162C (fr) | Nouveau n-pyridyl carboxamides et derives, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
EP2238110B1 (fr) | Dérivés de 5.6-bisaryl-2-pyr1dine-carboxamide, leur préparatio leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii | |
FR2714907A1 (fr) | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. | |
EP0051020A1 (fr) | Acides aza bicyclooctane carboxyliques, leur préparation et compositions pharmaceutiques les contenant | |
EP0690050A1 (fr) | Dérivés (thia)cycloalkyl(b) indoles comme inhibiteurs de la 5-lipoxygénase | |
CA2101058A1 (fr) | Composes a structure guanidique et composition pharmaceutique les contenant | |
EP1692114B1 (fr) | NOUVEAUX DERIVES DE LA BENZIMIDAZOLE ET D’IMIDAZO-PYRIDINE ET LEUR UTILISATION EN TANT QUE MEDICAMENT | |
EP0662971A1 (fr) | DERIVES DE 5H,10H-IMIDAZO 1,2-a]INDENO 1,2-e]PYRAZINE-4-ONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT | |
EP1092717A2 (fr) | Nouveaux dérivés polycycliques azaindolinques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP0114770A2 (fr) | Composés à noyau hétérocyclique diazoté, leur procédé de préparation et les médicaments, actifs sur le système nerveux central, qui en contiennent | |
EP0452204A1 (fr) | Nouveaux dérivés du 3-aminochromane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
WO1992021680A1 (fr) | Composes derives des aza-6-indoles, ligands du recepteur des benzodiazepines et medicaments le contenant | |
WO1995018817A1 (fr) | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant | |
EP0499527B1 (fr) | Composés dérivés des beta-carbolines ligands du récepteur des benzodiazépines ayant un effet agoniste inverse et antagoniste vis-à-vis des benzodiazépines et médicaments les contenant | |
EP0772615B1 (fr) | DERIVES D'ACIDE IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-2-CARBOXYLIQUE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT | |
EP0233800B1 (fr) | Dérivés d'imidazo[1,2-a]quinoléines, leur préparation et leur application en thérapeutique | |
EP0234970B1 (fr) | Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique | |
EP0172097A1 (fr) | Imidazo(1,2-a)quinolines, leur préparation et leur application en thérapeutique | |
EP0003920B1 (fr) | Thiéno (3,2-c) et thiéno (2,3-c)pyridines, leur procédé de préparation et leur application en thérapeutique | |
FR2459796A1 (fr) | Derives du benzimidazole et compositions pharmaceutiques les contenant | |
FR2619817A1 (fr) | Nouvelles beta carbolines 3-substituees, procede et intermediaires de preparation, application a titre de medicaments et compositions pharmaceutiques les renfermant | |
FR2508043A1 (fr) | Derives d'aporphine efficaces par voie orale et leur procede de fabrication | |
WO2022243651A1 (fr) | Nouveaux derives azaindole en tant qu'agents anticancereux | |
EP0161235A2 (fr) | Nouveaux dérivés de thiénopyridinone, leur procédé de préparation et compositions pharmaceutiques les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992912278 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2110299 Country of ref document: CA Ref document number: 08142489 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992912278 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992912278 Country of ref document: EP |